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Co-expression of Cancer Stem 
Cell Markers OCT4 and NANOG 
Predicts Poor Prognosis in Renal 
Cell Carcinomas
Arezoo Rasti  1, Mitra Mehrazma1,2, Zahra Madjd1,3, Maryam Abolhasani1,2,  
Leili Saeednejad Zanjani1 & Mojgan Asgari1,2
Many renal cancer patients experience disease recurrence after combined treatments or 
immunotherapy due to permanence of cancer stem cells (CSCs). This study was conducted to evaluate 
the expression patterns and clinical significance of octamer-binding transcription factor 4 (OCT4) 
and NANOG as the key stem cell factors in renal cell carcinoma (RCC). A total of 186 RCC tissues 
were immunostained on a tissue microarray (TMA) for the putative CSC markers OCT4 and NANOG. 
Subsequently, the correlation among the expression of these markers, the clinicopathological variables 
and survival outcomes were determined. OCT4 and NANOG were expressed in both the nucleus and the 
cytoplasm of RCC cells. Coexpression of OCT4 and NANOG in renal cancer was significantly associated 
with RCC subtypes. A significant association was found among nuclear coexpression of OCT4 and 
NANOG, worse PFS in RCC, and the clear cell renal cell carcinomas (ccRCC) subtype. The OCT4-nuclear 
high/NANOG-nuclear high phenotype in RCC and ccRCC subtype indicated aggressive tumor behavior and 
predicted a worse clinical outcome, which may be a useful biomarker to identify patients at high risk of 
postoperative recurrence and metastasis. Cytoplasmic expression of NANOG could be considered as a 
novel independent prognostic predictor in patients with renal cancer.
Renal cell carcinoma (RCC) is the most common malignant neoplasm of the kidney and is one of the most lethal 
genitourinary malignancies, with a 5-year survival rate of 67%1. RCC is divided into several histological subtypes 
including ccRCC, (the most common type) (70%), papillary (pRCC) (10–15%), and chromophobe (chRCC) 
(5%)2.
To date, the existence of CSCs has been demonstrated in a wide variety of malignancies including RCC, breast 
cancer, leukemia, glioblastoma, and liver carcinoma3–6. Based on the CSCs hypothesis, tumor initiation, mainte-
nance, and progression are driven by the unique characteristics of CSCs including multi-lineage differentiation, 
self-renewal, high expression of stemness genes, and drug resistance3.
It is generally proposed that CSCs originate either from progenitor cells that have acquired the ability to 
self-renew, or adult stem cells that have lost control of proliferation. However, several studies support the theory 
that CSCs arise from differentiated tumor cells that have undergone a process of dedifferentiation to become more 
stem-like4. Moreover, it seems that the key regulators in ESC also contribute to the pathogenesis of cancers by 
modulating the differentiation and self-renewal of CSCs5.
Octamer-binding transcription factor 4 (OCT4) and NANOG are key regulatory genes that maintain the 
pluripotency and self-renewal properties of normal stem cells and ESCs6. They induce the expression of each 
other, regulate cancer progression, and are biomarkers of CSCs7–11. OCT4 belongs to the POU (Pit-Oct-Unc) 
transcriptional factor family and plays a key role in stem cell differentiation and pluripotency by determining the 
fate of embryonic stem cells12. The expression of OCT4 has further been shown in human breast cancer stem-like 
cells, implicating its involvement in tumorigenesis and self-renewal by activating its downstream target genes, 
such as NANOG and SOX213. NANOG, a downstream target of OCT4, contributes to cell fate determination 
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of the pluripotent inner cell mass during embryonic development14. It promotes CSC characteristics in prostate 
cancer and regulates self-renewal of CSC in human hepatocellular carcinoma (HCC)5. Several lines of evidence 
have suggested that expression of OCT4 and NANOG is closely related to tumorigenesis, distant recurrence, and 
tumor metastasis after treatment15–19. Moreover, coexpression of OCT4 and NANOG is a strong independent 
predictor of unfavorable outcome and tumor recurrence in HCC patients and is associated with enhanced lung 
cancer malignancy and pancreatic carcinogenesis16,17,20.
There is growing evidence of correlation and crosstalk between tumor progression, metastasis, and stemness 
pathways; however, the functional and mechanistic significance of the overexpressed stem cell markers in cancer 
is still obscured and needs to be further clarified20. Prior studies have suggested that OCT4 and NANOG have a 
key role of tumorigenesis and prognosis of cancer. However, the prognostic significance of OCT4 and NANOG 
is not clearly defined in renal cancers. In this study, for the first time, we examined the expression patterns and 
clinical significance of both OCT4 and NANOG as CSC markers in RCC and its subtypes using tissue microarray 
(TMA) based immunohistochemistry (IHC) technique.
Materials and Methods
Patients’ Characteristics and Tissue Collection. RCC tissue samples were collected from Hasheminejad 
Kidney Center, a major university-based referral urology-nephrology center in Tehran, Iran, from 2007 to 2015. 
Patients who had undergone radical nephrectomy and had no history of preoperative hormone or radiation 
therapy were included in the current study. Based on the pathology findings and case records, the patient sam-
ples were categorized into 3 groups: ccRCC (n = 126), pRCC (n = 31), and chRCC (n = 29).The specimens were 
embedded in paraffin using a routine pathologic tissue processing technique. Medical records were retrieved to 
obtain the following clinicopathological parameters: tumor size, metastasis to regional lymph node and renal 
vein (RVI), microvasulcar invasion (MVI), the Gerota’s fascia, adrenal gland, peripheral fat, and renal pelvis 
involvements. In addition, pathologic tumor stage was defined according to the pTNM Classification for Renal 
Cell Carcinoma, 201321. Data of patients were kept fully de-identified in all steps. This study was approved by the 
Research Ethics Committee of Iran University of Medical Sciences.
Construction of Tissue Microarrays (TMAs). Renal tissue TMAs were prepared as described previ-
ously22. TMA blocks were constructed in 3 copies, each containing one sample from different regions of the 
tumor.
Immunohistochemistry (IHC) Staining. The expression of OCT4 and NANOG was immunohistochem-
ically evaluated using the protocol as described previously22–26. Briefly, sequential TMA sections were dewaxed 
at 60 °C for 20 minutes, rehydrated in xylenes, and underwent graded ethanol treatment. Antigen was retrieved 
by autoclaving tissue sections for 10 minutes in sodium citrate buffer (pH 6.0). Endogenous peroxidase and non-
reactive staining were blocked by 3% H2O2 for 20 minutes at room temperature. Then, the tissue sections were 
incubated overnight at 4 °C with the following antibody dilutions: anti-OCT4 antibody (ab18976; Abcam, UK) 
using a 1:100 dilution, and anti-NANOG antibody (ab109250; Abcam, UK) using a 1:150 dilution. After 3 washes 
in Tris-buffered saline (TBS), sections were incubated with anti-rabbit/anti-mouse envision (Dako, Denmark), 
as the secondary antibody, for 15 minutes. TMA slides were treated with 3,3′-diaminobenzidine (DAB, Dako) 
substrate as a chromogen for 10 minutes at room temperature. Sections were lightly counterstained with hema-
toxylin, dehydrated in alcohol, cleared with xylenes, and mounted. For negative controls, the primary antibody 
step was replaced with TBS, and only the secondary antibody was used. Human seminoma tissues were used as a 
positive control for OCT4 and NANOG staining.
Evaluation of Immunostaining. Two investigators (MA and AR), who had no previous knowledge 
of clinical and pathological parameters of the patients, examined the immunostained tissue arrays using a 
semi-quantitative scoring system in a coded manner. In difficult cases, scoring was confirmed by 2 observers and 
a consensus was achieved.
Scoring System. Immunostaining of OCT4 and NANOG were performed as described previously22. 
The intensities of OCT4 and NANOG staining were scored on a 4-point scale, ranging from absent to strong 
(0 = absent, 1 = weak, 2 = moderate, and 3 = strong), without previous knowledge of clinical and pathologic 
parameters. The overall score was obtained by H-score (Histochemical score) for each case by multiplying the 
intensity of staining by the percentage of positive cells, then, a final score of 0 to 300 was given to each core27. 
Three cut-off points (200, 160, and 200) were selected based on the median H-scores to categorize the samples 
as high or low nuclear OCT4 and nuclear or cytoplasmic NANOG expressions, respectively. Cytoplasmic OCT4 
expression was not categorized because the calculated median of H-score was 300.
Statistical Analysis. All data were analyzed using IBM Corp. (Released 2011. IBM SPSS Statistics for 
Windows, Version 20.0. Armonk, NY: IBM Corp.). We reported the categorical data by N, valid percent by %, and 
quantitative data as mean (SD) and median (Q1, Q3).
Nuclear and cytoplasmic OCT4 and NANOG expressions in ccRCC, pRCC, and chRCC tissues were com-
pared using Kruskal-Wallis test. Mann-Whitney U test was used for pairwise comparison between groups based 
on Bonferroni adjustment. Moreover, Pearson’s chi square test and Spearman’s correlation coefficient were used 
to analyze the association between OCT4 and NANOG expressions and clinicopathological parameters, as appro-
priate. Statistical significance was set at p < 0.05.
Disease specific survival (DSS) was measured from the date of nephrectomy to the date of death by RCC. 
Progression-free survival (PFS) was defined as the interval between the primary surgery and the last follow-up 
visit if the patient showed no evidence of disease, recurrence, or metastasis of RCC, or disease related death. DSS 
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and PFS curves were calculated using the Kaplan-Meier method. Log-rank test was used to compare the estimated 
curves between groups. The Cox proportional hazards model was used to determine which variables influenced 
DSS and PFS. Variables that significantly impacted survival in univariate analysis were included in the multivar-
iable (adjusted) analysis, and significance level was set at p < 0.05.
Ethical Approval. All procedures performed in studies involving human participants were in accordance 
with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki 
declaration, and its later amendments or comparable ethical standards. This research study was approved by the 
Research Ethics Committee of Iran University of Medical Sciences.
Informed Consent. Informed consent was obtained from all individual participants in the study.
Results
Patient Characteristics. Of the 186 RCC samples that were included in the present study, 126 (67.7%) 
were ccRCC, 31 (16.7%) pRCC, and 29 (15.6%) chRCC. A total of 130 (69.9%) samples were from male and 
56 (30.1%) from female patients. Overall, the mean age of the population was 55.2 (SD = 13.2) years (27–82). 
Tumor size was categorized into 4 groups: ≤4 cm, 4–7 cm, 7–10 cm, and ≥10 cm28. Median tumor size was 7 cm 
(5, 10), (1.5–21 cm). A total of 56 (30.1%) specimens were stage I, 19 (10.3%) stage II, 99 (53.2%) stage III, and 
12 (6.4%) stage IV. Moreover, 9 (4.8%) specimens were grade I (having a low-nuclear grade), 85 (45.7%) grade 
II, 57 (30.6%) grade III, and 6 (3.2%) had high-nuclear grade (grade IV). Regional lymph node involvement was 
found in 6 cases (3.2%), whereas 149 cases (80.1%) had no regional lymph node involvement, and in 29 cases 
(15.6%) no lymph node was dissected during surgery. Of the cases, 38 (20.4%) had MVI, 96 (51.6%) renal sinus 
involvement, and 65 (34.9%) tumoral necrosis. Other reported involvements were as follow: renal vein, 11 cases 
(5.9%); adrenal gland, 5 cases (2.7%); Gerota’s fascia, 6 cases (3.2%); renal pelvis, 12 cases (6.5%); and peripheral 
fat, 33 cases (17.7%).
Patients with RCC were evaluated for survival analysis, and it was found that according to the reverse K-M 
method, the median follow-up time of the surviving patients in PFS was 56.0 months; 95% CI, 51.24–60.75 while 
the mean follow-up time for DSS was 96.36 months; 95% CI, 89.35–103.36.
During the follow-up, disease-related death occurred in 25 patients (13.4%). Of the patients, 34 (18.2%) had 
history of metastasis, while recurrence was observed only in 6 patients (3.2%). Of the 186 patients, 96 (51.3%) had 
no history of recurrence, metastasis, or disease-related death.
Comparison of OCT4 and NANOG Expressions in RCC Subtypes. Analysis of TMA-based immu-
nohistochemistry staining demonstrated that expression of OCT4 and NANOG was localized to the nucleus and 
cytoplasm of the tumor cells. In RCC, the respective nuclear and cytoplasmic expressions rate for OCT4 were 
100% (186/186) and 95.2% (177/186), respectively, while the respective cytoplasmic and nuclear expressions rate 
for NANOG were 97.3% (181/186) and 82.8% (154/186), with varying levels of intensities. Immunohistochemical 
(IHC) analysis of OCT4 and NANOG expression in different RCC samples is illustrated in Figs 1 and 2.
The average nuclear and cytoplasmic expressions of OCT4 and NANOG (median H-score) in each subtype 
of RCC and the results of statistical tests are illustrated in Table 1. A statistically significant difference was found 
among the cytoplasmic expression of OCT4, the nuclear, and the cytoplasmic expression of NANOG in differ-
ent RCC subtypes (P < 0.001). Also, a statistically significant difference was observed between the cytoplasmic 
expression of OCT4 in RCC different grades ((III/IV vs. I/II)), (P = 0.022).
Association of OCT4 and NANOG Expressions with Clinicopathologic Parameters in 
RCC. Association of OCT4 and NANOG expression with clinicopathologic characteristics in RCC is summa-
rized in Table 2.
A statistically significant difference was observed between the nuclear and the cytoplasmic expression of 
NANOG in different RCC subtypes (P-values < 0.001 and <0.001, respectively). No other correlations were 
found between OCT and NANOG expressions and clinicopathologic characteristics.
Combined Analysis of OCT4/NANOG Populations. Dual staining of markers is the best method to 
present concurrent expression of markers on the same cells, as both OCT4 and NANOG markers are expressed 
on the nucleus and cytoplasm; however, we were unable to perform double staining with matched antibodies. 
Therefore, immunohistochemistry was performed on the serial sections of RCC TMA blocks to show the expres-
sion of these markers in the best possible way. A significant reciprocal correlation was observed between expres-
sion of OCT4 and NANOG (Spearman correlation coefficient, 0.362; P < 0.001); thus, we explored the cumulative 
staining patterns of these markers and their association with clinicopathologic parameters in different subtypes 
of renal cancer. The expression levels of OCT4 and NANOG were divided into 2 categories in 3 conditions. Next, 
we examined the association between nuclear OCT4 and nuclear and cytoplasmic NANOG expressions with 
clinicopathologic parameters (Table 3).
Prognostic Significance of OCT4 and NANOG Expressions. The 5-year DSS and PFS survival rates 
were 82.0% and 49.0% in low nuclear OCT4 expression, and 84.0% and 30.0% in high nuclear OCT4 expression. 
OCT4 nuclear overexpression was associated with shorter PFS survival than the low expression group (P = 0.010) 
(Fig. 3a).
In the survival analysis of NANOG nuclear expression, the 5-year DSS and PFS survival rates were 79.0% 
and 40.0% in cases with low nuclear NANOG expression, and 86.0% and 41.0% in cases with high nuclear 
NANOG expression. The 5-year DSS and PFS survival rates were 82.0% and 49.0% in cases with low cytoplasmic 
NANOG expression, and 82.0% and 34.0% in cases with high cytoplasmic NANOG expression. Cytoplasmic 
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Figure 1. Immunohistochemical (IHC) Analysis of OCT4 Expression in Different Renal Cell Carcinoma 
(RCC) Samples. RCC samples expressed OCT4 at various levels. Nuclear expression of OCT4 in clear cell 
RCC at various levels: weak (a), moderate (b), and strong (c); chromophobe RCC: moderate (d), and strong 
(e); papillary RCC: weak (f), and moderate (g). Cytoplasmic expression of OCT4 in clear cell RCC at various 
levels is as follows: weak (h), moderate (i), and strong (j), chromophobe RCC: moderate (k), and strong (l); and 
papillary RCC: moderate (m), and strong (n). IHC staining of seminoma tissue was presented as negative (o) 
and positive (p) controls. Figures are displayed with a magnification of 200x.
Figure 2. Immunohistochemical (IHC) Analysis of NANOG Expression in Different Renal Cell Carcinoma 
(RCC) Samples. RCC samples expressed NANOG at various levels. Nuclear expression of NANOG in clear cell 
RCC at various levels is as follows: weak (a), moderate (b), and strong (c); chromophobe RCC: weak (d), and 
moderate (e); and papillary RCC: weak (f), and strong (g). Cytoplasmic expression of NANOG in clear cell 
RCC at various levels is as follows: weak (h), moderate (i), and strong (j); chromophobe RCC: moderate (k), 
and strong (l); papillary RCC: moderate (m), and strong (n). IHC staining of seminoma tissue is presented as 
negative (o) and positive (p) controls. Figures are demonstrated with a magnification of 200x.
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overexpression of NANOG was associated with shorter PFS survival rate than the low expression group 
(P = 0.003) (Fig. 3b).
Then, the survival rate of patients with coexpression of OCT4 and NANOG (OCT4-nuclearhigh/
NANOG-nuclearhigh and OCT4-nuclearhigh/NANOG-cytoplasmichigh) was compared with that of other pheno-
types. Higher nuclear expressions of OCT and NANOG were associated with worse progression-free survival 
than other phenotypes (P = 0.004) (Fig. 4a).
Cox proportional univariate and multivariable analysis of relationships between prognostic variables and sur-
vival are presented in Table 4. Fuhrman grade and Tumor size were independent risk factor affecting the DSS of 
patients with RCC in multivariable analysis, with hazard ratios of 2.83 and 1.68 and p-values of 0.020 and 0.024, 
respectively. Clinical stage and cytoplasmic NANOG expression showed independent poor PFS, with hazard 
ratios of 2.41 and 1.58 and p-values of <0.001 and 0.041, respectively.
ccRCC ChRCC pRCC P valuea P valueb P valuec P valued
OCT4 Expression
(H- Score)
Nuclear Median (Q1, Q3) 200(160, 240)
210
(200, 300)
200
(180, 240) 0.169 — — —
Cytoplasmic Median (Q1, Q3) 200(200, 300)
300
(300, 300)
300
(300, 300) <0.001 <0.001 <0.001 0.568
NANOG Expression
(H- Score)
Nuclear Median (Q1, Q3) 100(30, 200)
200
(100, 200)
200
(100, 300) <0.001 0.001 0.004 0.899
Cytoplasmic Median (Q1, Q3) 200(140, 300)
300
(300, 300)
300
(200, 300) <0.001 <0.001 0.001 0.241
Table 1. Average OCT4 and NANOG expressions (H-Score) in ccRCC, chRCC and pRCC tissues. (Q1: the first 
quartile, Q3: the third quartile). aComparion between RCC subtypes using Kruskal-Wallis test. Comparisons 
between RCC subtypes Mann-Whitney U test based on Bonferroni adjustment: bComparion between ccRCC 
and ChRCC subtypes. cComparion between ccRCC and pRCC subtypes. dComparion between ChRCC and 
pRCC subtypes. Values in bold are statistically significant. ccRCC indicates clear cell Renal Cell Carcinoma; 
ChRCC, chromophob Renal Cell Carcinoma; pRCC, papillary Renal Cell Carcinoma.
Expression of OCT4 Expression of NANOG
Nuclear H-Score (N %)
*P 
value
Nuclear H-Score (N %)
*P 
value
Cytoplasmic H-Score N %)
*P value
Patient and
Tumor 
Charachteristics
Total No. 
Cases 186 
(N %)
Low
(≤200)
High
(200<)
Low
(≤160)
High
(160<)
Low
(≤200)
High
(200<)
Age (y)
≤55.2 87 (46.8) 55 (30.2) 29 (15.9) 0.644 40 (23.3) 41 (23.8) 0.359 42 (23.2) 42 (23.2) 0.882
>55.2 99 (53.2) 60 (33.0) 38 (20.9) 52 (30.2) 39 (22.7) 50 (27.6) 47 (26.0)
Sex
Male 130 (69.9) 54 (29.0) 76 (40.9) 1 58 (33.7) 63 (36.6) 503 67 (37.0) 60 (33.1) 0.516
Female 56 (30.1) 23 (12.4) 33 (17.7) 21 (12.2) 30 (17.4) 25 (13.8) 29 (16.0)
RCC subtypes
ccRCC 126 (67.7) 80 (44.0) 43 (23.6) 61 (35.5) 55 (32.0) 0.041 81 (44.8) 45 (29.4) <0.001
ChRCC 29 (15.6) 13 (7.1) 15 (8.2) 0.113 9 (5.2) 18 (10.5) 3 (1.7) 26 (14.4)
pRCC 31 (16.7) 22 (12.1) 9 (4.9) 9 (5.2) 20 (11.6) 8 (4.4) 18 (9.9)
Tumor size (cm)
<4 35 (18.8) 24 (13.2) 11 (6.0) 19 (11.0) 12 (7.0) 22 (12.2) 13 (7.2)
04-Jul 65 (34.9) 43 (23.6) 2 (11.0) 0.182 31 (18.0) 29 (16.9) 0.748 28 (15.5) 34 (18.8) 0.307
07-Oct 44 (23.7) 28 (15.4) 15 (8.2) 23 (13.4) 19 (11.0) 23 (12.7) 19 (10.5)
>10 42 (22.6) 20 (11.0) 21 (11.5) 19 (11.0) 20 (11.6) 19 (10.5) 23 (12.7)
Primary tumor (PT) Stage
I/II 75 (40.4) 50 (27.6) 22 (12.2) 0.159 35 (20.5) 29 (17.0) 0.874 38 (21.1) 34 (18.9) 0.651
III/IV 111 (59.6) 64 (35.4) 45 (24.9) 56 (37.7) 51 (29.8) 53 (29.4) 55 (30.6)
Histological Grade
I/II 94 (50.5) 65 (42.2) 27 (17.5) 0.169 49 (33.8) 37 (25.5) 1 44 (27.8) 49 (31.0) 1.000
III/IV 63 (33.9) 37 (24.0) 25 (16.2) 33 (22.8) 26 (17.9) 34 (21.5) 31 (19.6)
Table 2. Association of Nuclear expression (H-Score) of OCT4 and also nuclear and cytoplasmic expression 
(H-Score) of NANOG and clinical characteristics in RCC patients. *Significances are based on Pearson Chi-
square test. Values in bold are statistically significant. ccRCC indicates clear cell Renal Cell Carcinoma; chRCC, 
chromophob Renal Cell Carcinoma and pRCC, papillary Renal Cell Carcinoma.
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Association of OCT4 and NANOG Expressions with Survival Outcomes in ccRCC. Due to the 
limited number of occurred events in pRCC and ChRCC subtypes, DSS, PFS, and Cox proportional univariate 
and multivariable analyses were performed only for ccRCC patients. In Kaplan-Meier survival analysis, ccRCC 
patients, whose tumors expressed higher nuclear levels of OCT4 and NANOG, showed significantly poorer PFS 
than other phenotypes expressions (P = 0.040). (Fig. 4b). Tumor size and Fuhrman grade were the only significant 
risk factors affecting the DSS of patients with ccRCC in multivariable Cox proportional analysis, with hazard 
ratios of 1.22 and 1.47 and p-values of 0.001 and 0.005, respectively. Stage was the only significant risk factor 
affecting the PFS of patients with ccRCC in multivariable Cox proportional analysis, with hazard ratios of 2.35and 
p-value of 0.004.
Discussion
Many renal cancer patients experience disease recurrence after receiving combined treatments or immunotherapy 
due to the permanence of CSCs29. The expression of OCT4 or NANOG has been reported in the CSCs and been 
associated with a more aggressive tumor phenotype30. In the present study, for the first time, the expression levels 
of both OCT4 and NANOG were investigated in a well- characterized series of 186 tissues samples from 3 main 
subtypes of RCC; moreover, the impact of OCT4 and NANOG coexpression in RCC prognosis was evaluated.
Similar to previous reports, we found both nuclear and cytoplasmic expression pattern of OCT4 and NANOG 
in RCC samples31,32. This staining pattern of OCT4 may arise from the presence of an OCT4 isoform. OCT4 is 
known to have 2 isoforms, OCTA and OCTB. OCT4A is observed in the nucleus and OCT4B in the cytoplasm 
in prostate and cervical cancers32,33. Shao-Wen L.et al. demonstrated that both OCT4A and OCT4B are highly 
expressed at different subcellular locations. OCT4A appears to be responsible for stemness of CSCs and triggers 
carcinogenesis, while OCT4B promotes tumor growth by the regulation of angiogenesis, apoptosis, and epithelial 
to mesenchymal transition (EMT)33.
Our immunohistochemical analysis revealed that 100% of RCC samples were positive for Oct-4, 98% were 
positive for NANOG, 31.6% for OCT4-nuclearhigh/NANOG-nuclearhigh, and 47.6% were OCT4-nuclearhigh/
NANOG cytoplasmichigh phenotypes. Positive OCT4 or NANOG expression in renal cancer was not associated 
with known prognostic factors, such as clinical stage, or tumor size; however, it was significantly associated with 
histological subtype. Similar to our result, Bin YU et al. reported that the positive expression rate of OCT4 was 
not significantly correlated with T stage, but they did not refer to the expression pattern of OCT 4 in RCC sam-
ples. They demonstrated that RCC patients with high OCT4 and NANOG expressions in tumor tissues had sig-
nificantly lower survival time and metastasis-free survival rate31.
OCT4/NANOG Phenotypes
Patients 
and Tumor 
Characteristics
Total 
No.Cases 
186 (N %)
Condition1
*P value
Condition2
*P value
Condition3
*P value
Group1 Group2 Group1 Group2 Group1 Group2
OCT4Nuclearhigh/
NANOG-Nuclearhigh 
or OCT4Nuclearhigh/
NANOG-Cytoplasmichigh
Other 
phenotypes
OCT4-
Nuclearhigh/
NANOG 
Nuclearhigh
Other 
phenotypes
OCT4Nuclearhigh/
NANOG-
Cytoplasmichigh
Other 
phenotypes
RCC subtypes
ccRCC 126 (67.7) 57 (30.6) 69 (37.1)
0.012
34 (18.3) 92 (49.5)
0.116
53 (28.5) 73 (39.2)
0.004ChRCC 29 (15.6) 22 (11.8) 7 (3.8) 13 (7.0) 16 (8.6) 22 (11.8) 7 (3.8)
pRCC 31 (16.7) 16 (8.6) 15 (8.1) 12 (6.5) 19 (10.2) 14 (7.5) 17 (9.1)
Tumor size (cm)
<4 35 (18.8) 14 (7.5) 21 (11.3)
0.016
9 (4.8) 26 (14.0)
0.503
14 (7.5) 21 (11.3)
0.009
04-Jul 65 (34.9) 28 (15.1) 37 (19.9) 18 (9.7) 47 (25.3) 24 (12.9) 41 (22.0)
07-Oct 44 (23.7) 23 (12.4) 21 (11.3) 15 (8.1) 27 (14.5) 22 (11.8) 22 (11.8)
>10 42 (22.6) 30 (16.1) 12 (6.5) 59 (31.7) 27 (14.7) 29 (15.6) 13 (7.0)
Primary tumor (PT) Stage
I/II 74 (39.8) 35 (18.9) 38 (20.5)
0.547
21 (11.4) 52 (28.1)
0.52
31 (16.8) 42 (22.7)
0.231
III/IV 112 (60.2) 60 (32.4) 52 (28.1) 38 (20.5) 74 (40.0) 58 (31.4) 54 (29.2)
Histological Grade
I/II 94 (50.5) 38 (24.2) 56 (35.7)
0.7
23 (14.6) 71 (45.2)
0.111
34 (21.7) 60 (38.2)
0.05
III/IV 63 (33.9) 35 (22.3) 28 (17.8) 23 (14.6) 40 (25.5) 33 (21.0) 30 (19.1)
Microvascular invasion(MVI)
Positive 38 (20.4) 25 (14.2) 13 (7.4)
0.03
16 (9.1) 22 (12.5)
0.345
24 (13.6) 14 (8.0)
0.076
Negative 132 (71.0) 61 (34.7) 71 (40.3) 39 (22.2) 93 (52.8) 58 (33.0) 74 (42.0)
Table 3. Association between the OCT4 and NANOG phenotypes with clinicopathologic parameters. 
*Significances are based on Pearson Chi-square test. Values in bold are statistically significant. ccRCC indicates 
clear cell Renal Cell Carcinoma; chRCC, chromophob Renal Cell Carcinoma; pRCC, papillary Renal Cell 
Carcinoma.
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More importantly, the coexpression of OCT4 and NANOG in renal cancer was significantly associated with 
RCC subtypes, tumor size, and MVI in our study. The significant difference in nuclear OCT4 and nucleocyto-
plasmic NANOG expressions between ccRCC, compared with the chRCC and pRCC tumor samples, indicates 
that OCT4 and NANOG may act as a diagnostic markers to distinguish ccRCC from chRCC and pRCC subtypes.
It has been confirmed that ccRCC is more aggressive and associated with poorer prognosis than papillary and 
chromophobe RCC subtypes34. Most ccRCCs cases have deletions in the short arm of Chromosome 3, which are highly 
specific for ccRCC, and are not observed in any other RCC subtypes. These deletions result in the loss of specific small 
regions including the von Hippel–Lindau (VHL) gene35. On the other hand, VHL mutation induces overexpression 
of the hypoxia-inducible factor (HIF).The activation of vascular endothelial growth factor (VEGF) by HIF-1 has been 
observed as a notable mechanism involved in metastasis and hypoxia-induced angiogenesis29,36. HIF-2α has oncogenic 
function in ccRCC and promotes c-Myc, a vital oncogenic stem cell factor activity in pVHL −/− ccRCC, inhibits p53 
activity, and decreases subsequent p53-induced apoptosis upon γ-radiation, resulting in radio resistance, a significant 
feature of CSCs37. It is also involved in the expansion of CXCR4-positive cancer stem-like cells in RCC38. Previous stud-
ies have shown that hypoxic regulation of 2 stem cell factors, OCT4 and c-Myc, may powerfully impact CSC formation 
from cells expressing HIF-2α37,39. Like c-Myc and Oct4, NANOG, Sox2, and Klf4 are HIF-2α-dependent40. This mech-
anism may also occur in ccRCC. Further investigations are required to find a relationship among increased expressions 
of OCT4 and NANOG, hypoxia, HIF-2α expression, and CSC induction in ccRCC.
In this study, tumors with high nuclear expression of OCT4 or cytoplasmic NANOG expression had worse 
PFS survival. Bin Y. et al., in agreement with our study, demonstrated that RCC patients with higher expres-
sion of OCT4 and NANOG in tumor tissues had significantly lower survival time and metastasis-free survival 
Figure 3. Correlation Between OCT4 and NANOG Expressions and Survival Rates in Patients with Renal Cell 
Carcinoma. Progression-free survival (PFS) with nuclear OCT4 (a) and cytoplasmic NANOG (b) expressions 
(Nuclear and cytoplasmic expressions were grouped into low- vs. moderate- vs. high-expression levels).
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rate31. Interestingly, cytoplasmic NANOG expression was an independent prognostic factor for poor PFS in RCC 
patients, which was a novel finding of our study, raising the possibility of its utility as a prognostic biomarker for 
RCC. The follow-up period was not sufficiently long to allow definitive conclusions on some prognostic issues.
Overall, many preliminary studies have supported the fact that increased expression of OCT4 and NANOG 
correlates with poor prognosis, adverse clinicopathologic features, and survival time18,19. The expression of 
OCT4 has further been shown in human cancer stem-like cells, implicating its involvement in tumorigenesis and 
self-renewal through activating its downstream target genes13. Moreover, T. Hu et al. suggested that a reduction 
in OCT4 expression in lung CSCs induces the inhibition of tumor growth and apoptosis41. On the other hand, 
recent studies have shown that increased NANOG expression was observed in enriched CSCs. The discoveries of 
downstream regulatory pathways, directly or indirectly mediated by NANOG, indicate that NANOG regulates 
several aspects of cancer development, such as self-renewal, tumor cell proliferation, motility, EMT, escape from 
immune system, and drug resistance, which are all defined features for CSCs42.
Similar to our observations, coexpression of OCT4 and NANOG was found to be significantly associated 
with tumor aggressiveness and poor prognosis of several malignances including breast and lung cancers and 
glioma16,43,44. Importantly, a direct link was also found between OCT4 and NANOG. Together, these 2 markers 
can guide a cascade of pathways, which lead to the self-renewal and pluripotency characteristics of ESCs and 
contribute to tumor aggressiveness, poor outcome, and CSC characteristics8,45. Some recent studies have shown 
Figure 4. Influence of Coexpression of OCT4 and NANOG on Progression-Free Survival (PFS). PFS in renal 
cell carcinoma (RCC) patients (a), and PFS in clear cell renal cell carcinoma (ccRCC) patients (b). Patients with 
RCC (a) and ccRCC (b) showed worse PFS with high coexpression of nuclear OCT4 and nuclear NANOG in 
tumors.
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that ectopic coexpression of OCT4 and NANOG empowers cells with CSC properties including extensive prolif-
eration, self-renewal, high tumorigenic capacity, and drug resistance. OCT4 and NANOG significantly influence 
EMT change and contribute to tumor migration, invasion, and metastasis in vitro and in vivo16,20. On the other 
hand, Wang D. et al. demonstrated that knockdown of both OCT4 and NANOG expressions inhibit spontaneous 
changes in the expression of EMT-related genes and the migration of breast CSC in vitro44.
Evidence shows a direct link between the EMT and CSCs, both of which are involved in the generation of 
invasive cells and formation of distant metastases16. The majority of cancer cells in a tumor are non-tumorigenic, 
and therapy targeting these cells may cause tumor regression. However, if therapy fails to target the tumorigenic 
CSCs, these cells would persist after treatment and could regenerate the tumor, causing tumor recurrence or 
relapse. Therefore, eradication of cancers requires the elimination of CSCs. Advanced strategies that specifically 
target CSCs without damaging normal cells are urgently needed to improve current therapeutic treatments42.
Our data showed that RCC and ccRCC patients with higher coexpression of nuclear OCT4 and NANOG had 
worse PFS. Moreover, a significant difference was found in OCT4 and NANOG coexpression in ccRCC due to its 
worst prognosis compared with other RCC subtypes. Although our findings suggest that both nuclear expression 
of OCT4 and nucleocytoplasmic expressions of NANOG have implications in RCC prognosis, conducting further 
studies with larger sample size and prolonged follow-up time is highly recommended.
Conclusions
Our findings further suggest that OCT4 and NANOG coexpression may be valuable biomarkers in predicting the 
outcome of patients with renal cancer, especially in the ccRCC subtype. In the present study, a significant positive 
relationship was found between high expression of OCT4 and NANOG. Based on these findings, we suggest that there 
might be a positive involvement of OCT4/ NANOG, signaling pathways in tumor invasion and progression of RCC. 
Thus, it can be concluded that increased cytoplasmic expression of NANOG is an independent prognostic predictor in 
patients with RCC. Data revealed that abnormal elevated expression levels of key stemness factors, such as OCT4 and 
NANOG, in several types of CSCs, the role of these CSC markers in generation and maintenance of renal CSC, and 
the importance and therapeutic potential of targeting these stemness regulators in RCC have attracted the attention of 
the researchers. In addition, it would be helpful to gain knowledge about the pathological analysis of the subcellular 
localization of different OCT4 isoforms and the relationship of OCT4 and NANOG with renal CSCs properties, which 
will provide important clues to the diagnosis and prognosis of renal cancer and raise exciting questions for future 
experiments.
Feature
DSS PFS
Univariate Multiivariable Univariate Multiivariable
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI)
P
value
Age
(>55.2 vs. ≤55.2) 1.15 (0.46–2.87) 0.759 — — 1.68 (1.00–2.79) 0.046 — —
Sex
(male vs. female) 0.91 (0.33–2.55) 0.872 — — 0.93 (0.53–1.63) 0.804 — —
Clinical stage
(III/IV vs. I/II) 2.25 (0.85–5.97) 0.103 — — 2.40 (1.34–4.30) 0.003 2.41 (1.48–3.91) <0.001
Fuhrman grade
(III/IV vs. I/II) 3.70 (1.47–9.30) 0.005 2.83 (1.17–6.81) 0.020 1.73 (0.97–3.08) 0.063 — —
Tumor size 1.22 (1.08–1.38) 0.001 1.68 (1.07–2.66) 0.024 1.04 (0.96–1.12) 0.354 — —
MVI
(Present vs. Absent) 0.39 (0.14–1.04) 0.062 — — 1.05 (0.94–1.16) 0.354 — —
Nuclear OCT4 Expression
High vs. low 0.62 (0.20–1.88) 0.399 — —
1.60 
(0.94–
2.72)
0.079 —
Nuclear NANOG Expression
High vs. low 1.00 (0.37–2.68) 0.986 — — 1.38 (0.89–2.12) 0.141 — —
Cytoplasmic NANOG Expression
High vs. low 1.00 (0.39–2.54) 0.996 — — 1.86 (1.22–2.83) 0.004 1.58 (1.02–2.45) 0.041
OCT4 nuclear/NANOG nuclear
High vs. Other phenotypes 0.84 (0.30–2.35) 0.752 — — 0.51 (0.32–0.82) 0.005 0.55 (0.34–0.90) 0.018
OCT4 nuclear/NANOG cytoplasmic
High vs. Other phenotypes 0.83 (0.33–2.08) 0.706 — — 0.70 (0.46–1.64) 0.096 — —
Table 4. Univariate and multivariable analysis of disease free survival (DSS) and progression-free survival 
(PFS) in patients with renal cell carcinoma (RCC). Abbreviations: HR hazard ratio; CI confidence interval MVI; 
Microvascular invasion. Values in bold are statistically significant. The variables with P value less than 0.2 were 
included in multivariable analyses.
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